Market Cap 189.75M
Revenue (ttm) 1.88M
Net Income (ttm) -60.66M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,226.60%
Debt to Equity Ratio 0.00
Volume 65,100
Avg Vol 49,844
Day's Range N/A - N/A
Shares Out 28.62M
Stochastic %K 96%
Beta 1.24
Analysts Sell
Price Target $5.42

Company Profile

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The compa...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 949 409 7600
Website: imdxinc.com
Address:
2 International Plaza Dr., Suite 510, Nashville, United States
Bogwood
Bogwood Oct. 22 at 9:48 PM
$IMDX This opportunity continues to be incredibly reflexive as they will need another financing by 2H26. Josh and Andrea have done a great job evangelizing and executing this year
1 · Reply
RUNNINWILD
RUNNINWILD Oct. 22 at 7:06 PM
$IMDX beast
0 · Reply
JohnPDaly
JohnPDaly Oct. 22 at 2:34 PM
$LCTX $MDWD $IMDX “A sword-day, a red day, ere the sun rises!" J.R.R. Tolkien's The Lord of the Rings.
1 · Reply
RUNNINWILD
RUNNINWILD Oct. 22 at 1:27 AM
0 · Reply
cache1b
cache1b Oct. 21 at 11:05 PM
$IMDX @JohnPDaly Congrats... That truck driving thru the spread was bringing medical relief. I know, cuz I got some. It's a chronic condition, looking for less pain, and more gain. Please keep it coming. @LefDeppard
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 21 at 7:52 PM
$JWEL -6%[23%] $IMDX 5%[10%] $QH -4%[15%] $SLGB -4%[12%] $RANI -3%[31%] most notable movement into the final minutes of trading.
0 · Reply
RUNNINWILD
RUNNINWILD Oct. 21 at 2:08 PM
$IMDX broadwood owns approximately 40% BioRad approx 10%
0 · Reply
jackedmund99
jackedmund99 Oct. 21 at 2:05 PM
$IMDX obviously there’s a complete reevaluation of this company going on right now somebody you know out there realizes that this company has a bigger potential in the market cap indicates currently and that’s why they’re bidding the stock up. Anyone who has a Cell is getting taken out, I threw a few few shares out there just to test the waters and they were quickly grabbed something serious is happening.
1 · Reply
NY2CHI
NY2CHI Oct. 20 at 5:01 PM
$IMDX been on a straight tear. Can’t wait till fda approves this device next year. Then 🌕
0 · Reply
JohnPDaly
JohnPDaly Oct. 17 at 6:46 PM
$IMDX once again, as the only one here, I would like to congratulate me. Well, done.
3 · Reply
Latest News on IMDX
Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

May 19, 2025, 4:05 PM EDT - 5 months ago

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology


OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

May 12, 2025, 11:32 PM EDT - 5 months ago

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript


Oncocyte Reports Q1 2025 Results and Business Progress

May 12, 2025, 4:05 PM EDT - 5 months ago

Oncocyte Reports Q1 2025 Results and Business Progress


Oncocyte to Release First Quarter 2025 Results on May 12, 2025

May 7, 2025, 4:10 PM EDT - 6 months ago

Oncocyte to Release First Quarter 2025 Results on May 12, 2025


Oncocyte Provides Positive Update on Clinical Trial Progress

Apr 30, 2025, 8:30 AM EDT - 6 months ago

Oncocyte Provides Positive Update on Clinical Trial Progress


OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 6:53 PM EDT - 7 months ago

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript


Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Jan 6, 2025, 4:05 PM EST - 10 months ago

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney


OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:52 PM EST - 1 year ago

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript


OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 1:00 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript


OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

May 15, 2024, 10:15 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript


Oncocyte Reports First Quarter 2024 Financial Results

May 15, 2024, 4:05 PM EDT - 1 year ago

Oncocyte Reports First Quarter 2024 Financial Results


OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

Apr 12, 2024, 1:44 PM EDT - 1 year ago

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript


Oncocyte Reports Full Year 2023 Financial Results

Apr 12, 2024, 6:00 AM EDT - 1 year ago

Oncocyte Reports Full Year 2023 Financial Results


OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:36 AM EST - 2 years ago

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript


OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

Aug 10, 2023, 12:06 PM EDT - 2 years ago

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript


Oncocyte Announces 1-For-20 Reverse Stock Split

Jul 24, 2023, 1:35 PM EDT - 2 years ago

Oncocyte Announces 1-For-20 Reverse Stock Split


Oncocyte Begins Manufacturing Transplant Blood Test

Jun 27, 2023, 8:30 AM EDT - 2 years ago

Oncocyte Begins Manufacturing Transplant Blood Test


Oncocyte Reports First Quarter 2023 Financial Results

May 11, 2023, 8:00 AM EDT - 2 years ago

Oncocyte Reports First Quarter 2023 Financial Results


Oncocyte To Announce First Quarter 2023 Financial Results

Apr 27, 2023, 4:59 PM EDT - 2 years ago

Oncocyte To Announce First Quarter 2023 Financial Results


Oncocyte Presents New Data at AACR

Apr 18, 2023, 8:45 AM EDT - 2 years ago

Oncocyte Presents New Data at AACR


Oncocyte Announces Reduction in Force

Apr 12, 2023, 4:15 PM EDT - 2 years ago

Oncocyte Announces Reduction in Force


OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

Apr 3, 2023, 11:40 AM EDT - 2 years ago

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript


Bogwood
Bogwood Oct. 22 at 9:48 PM
$IMDX This opportunity continues to be incredibly reflexive as they will need another financing by 2H26. Josh and Andrea have done a great job evangelizing and executing this year
1 · Reply
RUNNINWILD
RUNNINWILD Oct. 22 at 7:06 PM
$IMDX beast
0 · Reply
JohnPDaly
JohnPDaly Oct. 22 at 2:34 PM
$LCTX $MDWD $IMDX “A sword-day, a red day, ere the sun rises!" J.R.R. Tolkien's The Lord of the Rings.
1 · Reply
RUNNINWILD
RUNNINWILD Oct. 22 at 1:27 AM
0 · Reply
cache1b
cache1b Oct. 21 at 11:05 PM
$IMDX @JohnPDaly Congrats... That truck driving thru the spread was bringing medical relief. I know, cuz I got some. It's a chronic condition, looking for less pain, and more gain. Please keep it coming. @LefDeppard
0 · Reply
_www_larval_com_
_www_larval_com_ Oct. 21 at 7:52 PM
$JWEL -6%[23%] $IMDX 5%[10%] $QH -4%[15%] $SLGB -4%[12%] $RANI -3%[31%] most notable movement into the final minutes of trading.
0 · Reply
RUNNINWILD
RUNNINWILD Oct. 21 at 2:08 PM
$IMDX broadwood owns approximately 40% BioRad approx 10%
0 · Reply
jackedmund99
jackedmund99 Oct. 21 at 2:05 PM
$IMDX obviously there’s a complete reevaluation of this company going on right now somebody you know out there realizes that this company has a bigger potential in the market cap indicates currently and that’s why they’re bidding the stock up. Anyone who has a Cell is getting taken out, I threw a few few shares out there just to test the waters and they were quickly grabbed something serious is happening.
1 · Reply
NY2CHI
NY2CHI Oct. 20 at 5:01 PM
$IMDX been on a straight tear. Can’t wait till fda approves this device next year. Then 🌕
0 · Reply
JohnPDaly
JohnPDaly Oct. 17 at 6:46 PM
$IMDX once again, as the only one here, I would like to congratulate me. Well, done.
3 · Reply
jackedmund99
jackedmund99 Oct. 17 at 3:26 PM
$IMDX I own over 100,000 shares at a cost near 240 been here for a while obviously some sophisticated money is coming into the stock as they know what’s about to happen with new oncology tests addressing a billion dollar market -Market cap is still micro
1 · Reply
JohnPDaly
JohnPDaly Oct. 16 at 6:32 PM
$IMDX 🎃💰🎃
0 · Reply
jackedmund99
jackedmund99 Oct. 16 at 6:17 PM
$IMDX gotta love the slow steady move I’m looking at his reevaluating the value of this company as it starts to rip up sales in $1 billion marketplace if they get a fraction of that business it deserves to be more than $200 million market especially with all the other products they got going on so that implies at least 87 to 8 dollars
1 · Reply
jackedmund99
jackedmund99 Oct. 16 at 3:51 PM
$IMDX stock moving towards new high in very tight hands small market cap going after billion dollar markets - I like the odds !
0 · Reply
JohnPDaly
JohnPDaly Oct. 15 at 5:49 PM
$IMDX 🎃🍁💰
0 · Reply
JohnPDaly
JohnPDaly Oct. 15 at 2:38 PM
$IMDX Looking more like a winner every day.
0 · Reply
RUNNINWILD
RUNNINWILD Oct. 14 at 7:58 PM
$IMDX it’s difficult to accumulate any significant amount of shares because it just pushes up the stock price by entering the buy orders 
2 · Reply
jackedmund99
jackedmund99 Oct. 14 at 7:21 PM
$IMDX about time they start reconsidering the possibilities that ste now available
1 · Reply
JohnPDaly
JohnPDaly Oct. 13 at 8:14 PM
iMDx Welcomes New VP Marketing to Prepare for Commercial Transplant Assay Launch – Insight Molecular Diagnostics Inc. $IMDX https://investors.imdxinc.com/news-releases/2025/10-13-2025-210530881
0 · Reply
jackedmund99
jackedmund99 Oct. 8 at 12:22 PM
$IMDX https://www.linkedin.com/posts/andreajames123_imdx-reports-kidney-transplant-patient-achieved-activity-7380995959973076992-fPb6?utm_medium=ios_app&rcm=ACoAAAGTUQEBIAend-uSLhvmiDbarslxama_K3o&utm_source=social_share_send&utm_campaign=copy_link
0 · Reply
NY2CHI
NY2CHI Oct. 7 at 8:14 PM
$IMDX starter position in this as of this am.
1 · Reply
topstockalerts
topstockalerts Oct. 6 at 2:14 PM
Insight Molecular Diagnostics shares rose Monday after the company reported study results published in the American Journal of Transplantation showing the effectiveness of its GraftAssure test in monitoring a kidney transplant patient with severe complications. The study described a 33-year-old transplant recipient who developed lymphoma but maintained stable graft function for about two years without immunosuppression while undergoing novel CD19 CAR-T therapy. Insight’s GraftAssure molecular test confirmed the absence of organ rejection throughout treatment. Chief Scientific Officer Dr. Ekke Schuetz said the case highlights the reliability of the company’s dd-cfDNA assay in rare clinical settings and noted that as transplant care incorporates new immunomodulatory therapies like CAR-T, the need for molecular monitoring will keep growing. $IMDX
0 · Reply